Brief: Mediwound Announces FDA Approval Of Nexobrid® For The Treatment Of Severe Thermal Burns In Adults

Vericel

29/12/2022 18:48

Dec 29 (Reuters) - Mediwound Ltd  MDWD.O :
    * MEDIWOUND ANNOUNCES FDA APPROVAL OF NEXOBRID® FOR THE
TREATMENT
OF SEVERE THERMAL BURNS IN ADULTS
    * MEDIWOUND LTD- NEXOBRID IS ANTICIPATED TO BE COMMERCIALLY
AVAILABLE IN U.S. IN Q2 OF 2023
    * MEDIWOUND LTD - STUDY MET ITS PRIMARY ENDPOINT OF
INCIDENCE OF
≥95% ESCHAR REMOVAL COMPARED TO GEL VEHICLE, AS WELL AS ALL
SECONDARY ENDPOINTS
    * MEDIWOUND LTD- WILL RECEIVE A $7.5 MILLION MILESTONE
PAYMENT
FROM VERICEL CORPORATION, TRIGGERED BY FDA APPROVAL OF NEXOBRID

Source text for Eikon:  ID:nGNX9xRFTG 
Further company coverage:  MDWD.O 
 ((Reuters.Briefs@thomsonreuters.com;))